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We thank Dr Arbit for his interest in our article. We have
demonstrated that argatroban reduces peritumoral brain
edema, tumor mass and improves tumor-induced neurological
deficits in a rat glioma model [1,2]. As Dr Arbit suggests,
argatroban may also be useful to reduce the deep vein
thrombosis that can occur in glioma patients [3].
Argatroban is a small molecule that binds to the active site
of thrombin [4]. Its size may facilitate its entry across the
disrupted blood–brain barrier or blood–glioma barrier. Un-
like heparin, argatroban is a direct thrombin inhibitor that
does not require a cofactor to inhibit thrombin. Argatroban
has a lower hemorrhagic potential in vivo than other thrombin
inhibitors such as heparin or hirudin [4]. In a previous study,
we found that argatroban reduces brain edema induced by
intracerebral hemorrhage and does not exacerbate hemor-
rhage in rats [5].
As noted by Dr Arbit, one of the disadvantages of using
argatroban is that it should be administered intravenously.
Melagatran is another low molecule direct thrombin inhibitor. It
can be administered orally in the form of a pro-drug, ximelaga-
tran, which is rapidly converted to the active molecule [6]. As Dr
Arbit suggests, it will be very important to determine whether
ximelagatran/melagatranwill also be effective in glioma treatment.
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